Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype
- 1 October 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 10 (10), 1369-1379
- https://doi.org/10.1158/1541-7786.mcr-12-0216
Abstract
The aryl hydrocarbon receptor (AhR) has been shown to play a role in an increasing number of cellular processes. Recent reports have linked the AhR to cell proliferation, cytoskeletal arrangement, and tumor invasiveness in various tumor cell types. The AhR plays a role in the de-repression of the interleukin (IL)6 promoter in certain tumor cell lines, allowing for increased transcriptional activation by cytokines. Here, we show that there is a significant level of constitutive activation of the AhR in cells isolated from patients with head and neck squamous cell carcinoma (HNSCC). Constitutive activation of the AhR in HNSCCs was blocked by antagonist treatment, leading to a reduction in IL6 expression. In addition, the AhR exhibits a high level of expression in HNSCCs than in normal keratinocytes. These findings led to the hypothesis that the basal AhR activity in HNSCCs plays a role in the aggressive phenotype of these tumors and that antagonist treatment could mitigate this phenotype. This study provides evidence that antagonism of the AhR in HNSCC tumor cells, in the absence of exogenous receptor ligands, has a significant effect on tumor cell phenotype. Treatment of these cell lines with the AhR antagonists 6, 2′, 4′-trimethoxyflavone, or the more potent GNF351, decreased migration and invasion of HNSCC cells and prevented benzo[a]pyrene-mediated induction of the chemotherapy efflux protein ABCG2. Thus, an AhR antagonist treatment has been shown to have therapeutic potential in HNSCCs through a reduction in aggressive cell phenotype. Mol Cancer Res; 10(10); 1369–79. ©2012 AACR.Keywords
Other Versions
This publication has 49 references indexed in Scilit:
- The Uremic Toxin 3-Indoxyl Sulfate Is a Potent Endogenous Agonist for the Human Aryl Hydrocarbon ReceptorBiochemistry, 2009
- Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9BMC Cell Biology, 2009
- The Dioxin Receptor Regulates the Constitutive Expression of theVav3Proto-Oncogene and Modulates Cell Shape and AdhesionMolecular Biology of the Cell, 2009
- Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapyAdvanced Drug Delivery Reviews, 2009
- 12(R)-Hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic Acid [12(R)-HETE], an Arachidonic Acid Derivative, Is an Activator of the Aryl Hydrocarbon ReceptorMolecular Pharmacology, 2008
- Interleukin‐6 predicts recurrence and survival among head and neck cancer patientsCancer, 2008
- Inflammatory Signaling and Aryl Hydrocarbon Receptor Mediate Synergistic Induction of Interleukin 6 in MCF-7 CellsCancer Research, 2008
- The Aryl Hydrocarbon Receptor Complex and the Control of Gene ExpressionCritical Reviews™ in Eukaryotic Gene Expression, 2008
- Role of metalloproteins in the clinical management of head and neck squamous cell carcinomaHead & Neck, 2007
- TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) causes increases in protein kinases particularly protein kinase C in the hepatic plasma membrane of the rat and the guinea pigBiochemical and Biophysical Research Communications, 1985